Medinol Overview
Medinol is dedicated to the science of cardiovascular intervention. Medinol develops, manufactures, and markets EluNIR, an elastomeric drug-eluting stent made from a thin cobalt-chrome alloy and recognized for its optimal balance between flexibility, conformability, scaffolding, and low metal footprint. EluNIR offers a new level of uniform drug elution and surface quality and demonstrated excellent clinical outcomes and long-term safety profile in clinical studies. EluNIR features the novel Flexx catheter technology with a visible metallic spring tip that eliminates tip flare-out and buckling. Flexx overcomes standard polymer tip limitations, offering both superb flexibility and uncompromised crossability, resulting in unprecedented ease of delivery even in complex anatomies.
Latest News
growth-positive
Microtech to unveil implantable microsensor technology at 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting
Microtech, a subsidiary of Medinol, Inc., announced that its implantable microsensor platform will be presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT). The platform is a new class of sensor technology that can be integrated onto any existing device, turning it into a smart, data-gathering device. The technology can be used for various medical conditions, providing wider healthcare access and reducing the need for office/hospital visits. The CEO of Medinol, Dr. Yoram Richter, will be presenting the technology platform.
CustomersPartners
growth-positive
Medinol stent performs just as well as Medtronic Resolute, study says
A clinical study shows that Medinols EluNIR drug-eluting stent performs just as well as Medtronics Resolute Integrity or Resolute Onyx stents. The study involved 2,221 people and compared the ridaforolimus-eluting stent from Medinol with the zotarolimus-eluting stent from Medtronic. Medinols EluNIR stent was approved by the FDA in 2017 and the first commercial implants took place in the U.S. in early 2018. The stent is distributed in the U.S. by Cardinal Healths Cordis business.
PartnersCustomers
growth-positive
Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR™ Drug-Eluting Stent
Cordis, a Cardinal Health company, and Medinol have announced the first commercial cases using the EluNIR™ drug-eluting stent (DES) in the United States. The stent was approved for the treatment of patients with narrowing or blockages in their coronary arteries and is being distributed by Cordis. Cordis and Medinol have a long-term distribution agreement that gives Cordis the rights to sell Medinols coronary stent portfolio in the U.S. The EluNIR™ stent offers ease of delivery and is designed for use in highly complex cases. The first commercial cases were performed at New York-Presbyterian Hospital/Columbia University Medical Center and the Piedmont Heart Institute. Medinol has an extensive patent portfolio and is a leading developer in the cardiovascular intervention technology space.
Customers
growth-positive
FDA approves Medinol's medicated stent
Medinol, owned by Kobi and Judith Richter, has received FDA approval for its EluNIR drug-eluting stent. The stent is designed with a novel metallic spring tip and the narrowest strut width of any stent on the US market. Medinols new stent is expected to improve the companys competitiveness in the growing medicated stent market. Medinol was able to develop the stent after winning $750 million in damages from Boston Scientific in a lawsuit. The companys annual revenue is believed to be in the hundreds of millions of dollars. The EluNIR stent has demonstrated a low failure rate and zero percent rate of late stent thrombosis. This FDA approval marks the first for a privately held company based outside of the US.
CustomersPartners
growth-positive
Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System
Cordis, a Cardinal Health company, and Medinol have announced the FDA approval of the EluNIR drug-eluting stent (DES) for the treatment of patients with narrowing or blockages to their coronary arteries. The stent system is designed with a novel metallic spring tip and the narrowest strut width of any stent on the U.S. market. The EluNIR DES demonstrated outstanding efficacy and safety results in two randomized clinical trials. Cardinal Healths long-term distribution agreement with Medinol enables Cordis to sell Medinols coronary stent portfolio in the U.S.
PartnersCustomers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Mature |
| Rounds | 0 |
| Investors | 0 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | medinol.com |
| Careers | Careers page |
Locations
Hartom Street 8, Jerusalem, Israel
Kiryat Atidim, Building 8 Tel Aviv-Yafo, Israel
13395 Voyager Pkwy, Colorado Springs, CO 80921, USA
Photos & Videos
2 item(s)
Medinol Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCommerce & RetailDistribution ChannelsDistributorCore Technology
Materials & SubstancesAlloysPolymersTags (11)
hospitalsdrug-deliverysustained-releasecardiologymedical-devicessurgerystentcardiovascularpolymerscathetersalloysGeographic Markets
GlobalMedinol Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Mature
Funding stage
0
Total rounds
0
Investors
Medinol Lifecycle
Medinol News
7 articles
growth-positive
Microtech to unveil implantable microsensor technology at 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting
Microtech, a subsidiary of Medinol, Inc., announced that its implantable microsensor platform will be presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT). The platform is a new class of sensor technology that can be integrated onto any existing device, turning it into a smart, data-gathering device. The technology can be used for various medical conditions, providing wider healthcare access and reducing the need for office/hospital visits. The CEO of Medinol, Dr. Yoram Richter, will be presenting the technology platform.
CustomersPartners
growth-positive
Medinol stent performs just as well as Medtronic Resolute, study says
A clinical study shows that Medinols EluNIR drug-eluting stent performs just as well as Medtronics Resolute Integrity or Resolute Onyx stents. The study involved 2,221 people and compared the ridaforolimus-eluting stent from Medinol with the zotarolimus-eluting stent from Medtronic. Medinols EluNIR stent was approved by the FDA in 2017 and the first commercial implants took place in the U.S. in early 2018. The stent is distributed in the U.S. by Cardinal Healths Cordis business.
PartnersCustomers
growth-positive
Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR™ Drug-Eluting Stent
Cordis, a Cardinal Health company, and Medinol have announced the first commercial cases using the EluNIR™ drug-eluting stent (DES) in the United States. The stent was approved for the treatment of patients with narrowing or blockages in their coronary arteries and is being distributed by Cordis. Cordis and Medinol have a long-term distribution agreement that gives Cordis the rights to sell Medinols coronary stent portfolio in the U.S. The EluNIR™ stent offers ease of delivery and is designed for use in highly complex cases. The first commercial cases were performed at New York-Presbyterian Hospital/Columbia University Medical Center and the Piedmont Heart Institute. Medinol has an extensive patent portfolio and is a leading developer in the cardiovascular intervention technology space.
Customers
growth-positive
FDA approves Medinol's medicated stent
Medinol, owned by Kobi and Judith Richter, has received FDA approval for its EluNIR drug-eluting stent. The stent is designed with a novel metallic spring tip and the narrowest strut width of any stent on the US market. Medinols new stent is expected to improve the companys competitiveness in the growing medicated stent market. Medinol was able to develop the stent after winning $750 million in damages from Boston Scientific in a lawsuit. The companys annual revenue is believed to be in the hundreds of millions of dollars. The EluNIR stent has demonstrated a low failure rate and zero percent rate of late stent thrombosis. This FDA approval marks the first for a privately held company based outside of the US.
CustomersPartners
growth-positive
Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System
Cordis, a Cardinal Health company, and Medinol have announced the FDA approval of the EluNIR drug-eluting stent (DES) for the treatment of patients with narrowing or blockages to their coronary arteries. The stent system is designed with a novel metallic spring tip and the narrowest strut width of any stent on the U.S. market. The EluNIR DES demonstrated outstanding efficacy and safety results in two randomized clinical trials. Cardinal Healths long-term distribution agreement with Medinol enables Cordis to sell Medinols coronary stent portfolio in the U.S.
PartnersCustomers
growth-positive
EluNIR Drug-Eluting Coronary Stent from Medinol Wins European Clearance
Medinols EluNIR drug eluting stent has received CE Mark approval in Europe. The device is designed to prevent restenosis and has features such as a flexible tip and minimal metal material. The device showed outstanding results in clinical studies. Medinol is a medical device company based in Tel Aviv, Israel.
Customers
growth-positive
Ridaforolimus-eluting stent safe, effective in symptomatic CAD treatment
A novel ridaforolimus-eluting stent developed by Medinol Ltd. was found to be noninferior to a zotarolimus-eluting stent in a clinical trial. The trial evaluated the safety and efficacy of the stent among patients with symptomatic CAD. The results showed that the new stent had similar outcomes to contemporary DES used in clinical practice. The trial was funded by Medinol Ltd. and the lead researcher, David E. Kandzari, has received consultant fees from various medical device companies. The article does not mention any specific customers or partners.
Customers
Medinol Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 137 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.
Medinol Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 512622994 |
| Crunchbase | Medinol |
| Phone | +97237679000 |
| Creator | Tamar Weiss |
| Creator email | tamar.e.weiss@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-12-27T00:00:00.000Z |
| Created | 2014-07-24T00:00:00.000Z |
| Claimed | Yes |